Jack Allen
Stock Analyst at Baird
(1.49)
# 3,431
Out of 5,179 analysts
43
Total ratings
38.24%
Success rate
-8.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jack Allen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACLX Arcellx | Downgrades: Neutral | $106 → $115 | $114.57 | +0.38% | 6 | Feb 23, 2026 | |
| CRSP CRISPR Therapeutics AG | Maintains: Neutral | $52 → $44 | $45.75 | -3.83% | 3 | Nov 11, 2025 | |
| VOR Vor Biopharma | Upgrades: Outperform | $20 → $64 | $14.48 | +341.99% | 5 | Oct 15, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Outperform | $7 → $12 | $4.07 | +194.84% | 5 | Oct 2, 2025 | |
| FATE Fate Therapeutics | Maintains: Neutral | $5 → $4 | $1.17 | +241.88% | 2 | May 14, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Outperform | $12 → $9 | $2.26 | +298.23% | 3 | May 14, 2025 | |
| INKT MiNK Therapeutics | Maintains: Outperform | $80 → $40 | $11.02 | +262.98% | 2 | Nov 15, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Neutral | $24 → $18 | $12.37 | +45.51% | 2 | Oct 25, 2024 | |
| TIL Instil Bio | Reiterates: Outperform | $180 | $7.79 | +2,210.65% | 9 | Sep 16, 2024 | |
| MREO Mereo BioPharma Group | Initiates: Outperform | $8 | $0.33 | +2,330.87% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $84 | $29.44 | +185.33% | 1 | Oct 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $1.49 | +235.57% | 1 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $3.08 | - | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $6 → $9 | $3.96 | +127.27% | 1 | Oct 7, 2021 |
Arcellx
Feb 23, 2026
Downgrades: Neutral
Price Target: $106 → $115
Current: $114.57
Upside: +0.38%
CRISPR Therapeutics AG
Nov 11, 2025
Maintains: Neutral
Price Target: $52 → $44
Current: $45.75
Upside: -3.83%
Vor Biopharma
Oct 15, 2025
Upgrades: Outperform
Price Target: $20 → $64
Current: $14.48
Upside: +341.99%
Taysha Gene Therapies
Oct 2, 2025
Maintains: Outperform
Price Target: $7 → $12
Current: $4.07
Upside: +194.84%
Fate Therapeutics
May 14, 2025
Maintains: Neutral
Price Target: $5 → $4
Current: $1.17
Upside: +241.88%
Allogene Therapeutics
May 14, 2025
Maintains: Outperform
Price Target: $12 → $9
Current: $2.26
Upside: +298.23%
MiNK Therapeutics
Nov 15, 2024
Maintains: Outperform
Price Target: $80 → $40
Current: $11.02
Upside: +262.98%
Intellia Therapeutics
Oct 25, 2024
Maintains: Neutral
Price Target: $24 → $18
Current: $12.37
Upside: +45.51%
Instil Bio
Sep 16, 2024
Reiterates: Outperform
Price Target: $180
Current: $7.79
Upside: +2,210.65%
Mereo BioPharma Group
Jun 13, 2024
Initiates: Outperform
Price Target: $8
Current: $0.33
Upside: +2,330.87%
Oct 31, 2023
Initiates: Outperform
Price Target: $84
Current: $29.44
Upside: +185.33%
Nov 2, 2022
Initiates: Outperform
Price Target: $5
Current: $1.49
Upside: +235.57%
May 18, 2022
Upgrades: Outperform
Price Target: n/a
Current: $3.08
Upside: -
Oct 7, 2021
Upgrades: Outperform
Price Target: $6 → $9
Current: $3.96
Upside: +127.27%